Titre : Villes

Villes : Questions médicales fréquentes

Termes MeSH sélectionnés :

Visual Field Tests
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Villes : Questions médicales les plus fréquentes", "headline": "Villes : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Villes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-31", "dateModified": "2025-04-27", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Villes" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Régions géographiques", "url": "https://questionsmedicales.fr/mesh/D005842", "about": { "@type": "MedicalCondition", "name": "Régions géographiques", "code": { "@type": "MedicalCode", "code": "D005842", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Baltimore", "alternateName": "Baltimore", "url": "https://questionsmedicales.fr/mesh/D015142", "about": { "@type": "MedicalCondition", "name": "Baltimore", "code": { "@type": "MedicalCode", "code": "D015142", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.100" } } }, { "@type": "MedicalWebPage", "name": "Pékin", "alternateName": "Beijing", "url": "https://questionsmedicales.fr/mesh/D000068476", "about": { "@type": "MedicalCondition", "name": "Pékin", "code": { "@type": "MedicalCode", "code": "D000068476", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.114" } } }, { "@type": "MedicalWebPage", "name": "Boston", "alternateName": "Boston", "url": "https://questionsmedicales.fr/mesh/D001900", "about": { "@type": "MedicalCondition", "name": "Boston", "code": { "@type": "MedicalCode", "code": "D001900", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.210" } } }, { "@type": "MedicalWebPage", "name": "Chicago", "alternateName": "Chicago", "url": "https://questionsmedicales.fr/mesh/D002641", "about": { "@type": "MedicalCondition", "name": "Chicago", "code": { "@type": "MedicalCode", "code": "D002641", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.305" } } }, { "@type": "MedicalWebPage", "name": "District de Columbia", "alternateName": "District of Columbia", "url": "https://questionsmedicales.fr/mesh/D004219", "about": { "@type": "MedicalCondition", "name": "District de Columbia", "code": { "@type": "MedicalCode", "code": "D004219", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.429" } } }, { "@type": "MedicalWebPage", "name": "Los Angeles", "alternateName": "Los Angeles", "url": "https://questionsmedicales.fr/mesh/D015141", "about": { "@type": "MedicalCondition", "name": "Los Angeles", "code": { "@type": "MedicalCode", "code": "D015141", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.565" } } }, { "@type": "MedicalWebPage", "name": "Nouvelle-Orléans", "alternateName": "New Orleans", "url": "https://questionsmedicales.fr/mesh/D055820", "about": { "@type": "MedicalCondition", "name": "Nouvelle-Orléans", "code": { "@type": "MedicalCode", "code": "D055820", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.697" } } }, { "@type": "MedicalWebPage", "name": "New York (ville)", "alternateName": "New York City", "url": "https://questionsmedicales.fr/mesh/D009519", "about": { "@type": "MedicalCondition", "name": "New York (ville)", "code": { "@type": "MedicalCode", "code": "D009519", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.741" } } }, { "@type": "MedicalWebPage", "name": "Philadelphie", "alternateName": "Philadelphia", "url": "https://questionsmedicales.fr/mesh/D015143", "about": { "@type": "MedicalCondition", "name": "Philadelphie", "code": { "@type": "MedicalCode", "code": "D015143", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.820" } } }, { "@type": "MedicalWebPage", "name": "San Francisco", "alternateName": "San Francisco", "url": "https://questionsmedicales.fr/mesh/D012495", "about": { "@type": "MedicalCondition", "name": "San Francisco", "code": { "@type": "MedicalCode", "code": "D012495", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.875" } } }, { "@type": "MedicalWebPage", "name": "Séoul", "alternateName": "Seoul", "url": "https://questionsmedicales.fr/mesh/D066106", "about": { "@type": "MedicalCondition", "name": "Séoul", "code": { "@type": "MedicalCode", "code": "D066106", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.887" } } }, { "@type": "MedicalWebPage", "name": "Tokyo", "alternateName": "Tokyo", "url": "https://questionsmedicales.fr/mesh/D014041", "about": { "@type": "MedicalCondition", "name": "Tokyo", "code": { "@type": "MedicalCode", "code": "D014041", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.900" } } } ], "about": { "@type": "MedicalCondition", "name": "Villes", "alternateName": "Cities", "code": { "@type": "MedicalCode", "code": "D002947", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Divya Seth", "url": "https://questionsmedicales.fr/author/Divya%20Seth", "affiliation": { "@type": "Organization", "name": "Division of Allergy/Immunology, Department of Pediatrics, Children's Hospital of Michigan, Wayne State University School of Medicine, 3950 Beaubien, 4th Floor, Pediatric Specialty Building, Detroit, MI 48201, USA. Electronic address: dseth@dmc.org." } }, { "@type": "Person", "name": "Shweta Saini", "url": "https://questionsmedicales.fr/author/Shweta%20Saini", "affiliation": { "@type": "Organization", "name": "Division of Hospital Medicine, Department of Pediatrics, Children's Hospital of Michigan, Wayne State University School of Medicine, Detroit, MI, USA." } }, { "@type": "Person", "name": "Pavadee Poowuttikul", "url": "https://questionsmedicales.fr/author/Pavadee%20Poowuttikul", "affiliation": { "@type": "Organization", "name": "Division of Allergy/Immunology, Department of Pediatrics, Children's Hospital of Michigan, Wayne State University School of Medicine, Detroit, MI, USA." } }, { "@type": "Person", "name": "Marc Barthelemy", "url": "https://questionsmedicales.fr/author/Marc%20Barthelemy", "affiliation": { "@type": "Organization", "name": "Université Paris-Saclay, CEA, CNRS, Institut de Physique Théorique, 91191 Gif-sur-Yvette, France." } }, { "@type": "Person", "name": "Sasha Khomenko", "url": "https://questionsmedicales.fr/author/Sasha%20Khomenko", "affiliation": { "@type": "Organization", "name": "Institute for Global Health, Barcelona, Spain; Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Progressive Paracentral Visual Field Loss at Low Intraocular Pressures Following LASIK.", "datePublished": "2024-06-14", "url": "https://questionsmedicales.fr/article/39141409", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/IJG.0000000000002395" } }, { "@type": "ScholarlyArticle", "name": "Smoking Cessation May Reduce Risk of Visual Field Progression in Heavy Smokers.", "datePublished": "2022-08-02", "url": "https://questionsmedicales.fr/article/35939832", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/IJG.0000000000002092" } }, { "@type": "ScholarlyArticle", "name": "Correlation between Interocular Asymmetry of Corneal Hysteresis and Visual Field Defect in Glaucoma.", "datePublished": "2023-02-09", "url": "https://questionsmedicales.fr/article/36758563", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3341/kjo.2022.0120" } }, { "@type": "ScholarlyArticle", "name": "Comparing the Accuracy of Peripapillary OCT Scans and Visual Fields to Detect Glaucoma Worsening.", "datePublished": "2023-02-06", "url": "https://questionsmedicales.fr/article/36754173", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ophtha.2023.01.021" } }, { "@type": "ScholarlyArticle", "name": "Two-Year Visual Field Outcomes of the Treatment of Advanced Glaucoma Study (TAGS).", "datePublished": "2022-10-10", "url": "https://questionsmedicales.fr/article/36228777", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ajo.2022.09.011" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Régions géographiques", "item": "https://questionsmedicales.fr/mesh/D005842" }, { "@type": "ListItem", "position": 3, "name": "Villes", "item": "https://questionsmedicales.fr/mesh/D002947" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Villes - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Villes", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-06", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Villes", "description": "Comment évaluer l'impact de la pollution urbaine sur la santé ?\nQuels tests sont utilisés pour diagnostiquer les maladies liées aux villes ?\nComment identifier les zones à risque sanitaire en ville ?\nQuels indicateurs de santé sont pertinents en milieu urbain ?\nComment évaluer l'accès aux soins en ville ?", "url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Visual+Field+Tests&page=4#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Villes", "description": "Quels symptômes sont liés à la pollution de l'air ?\nComment la vie urbaine affecte-t-elle la santé mentale ?\nQuels symptômes sont associés à la chaleur urbaine ?\nQuels signes indiquent une mauvaise qualité de l'eau en ville ?\nQuels symptômes sont liés à l'isolement social en ville ?", "url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Visual+Field+Tests&page=4#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Villes", "description": "Comment prévenir les maladies liées à la pollution en ville ?\nQuelles mesures peuvent réduire le stress urbain ?\nComment améliorer la qualité de l'eau en milieu urbain ?\nQuelles stratégies aident à prévenir les coups de chaleur ?\nComment favoriser la santé mentale en milieu urbain ?", "url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Visual+Field+Tests&page=4#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Villes", "description": "Quels traitements sont efficaces contre les maladies respiratoires urbaines ?\nComment traiter les effets de la chaleur extrême en ville ?\nQuels traitements sont disponibles pour le stress urbain ?\nComment traiter les maladies liées à l'eau contaminée ?\nQuels traitements sont recommandés pour l'anxiété urbaine ?", "url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Visual+Field+Tests&page=4#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Villes", "description": "Quelles complications peuvent survenir à cause de la pollution ?\nQuels risques de santé sont liés à l'isolement social ?\nQuelles complications peuvent résulter de la chaleur extrême ?\nComment la qualité de l'eau affecte-t-elle la santé ?\nQuelles complications sont liées à la vie urbaine ?", "url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Visual+Field+Tests&page=4#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Villes", "description": "Quels facteurs de risque sont associés à la pollution urbaine ?\nComment le stress urbain influence-t-il la santé ?\nQuels sont les risques liés à la chaleur en milieu urbain ?\nQuels facteurs augmentent le risque de maladies infectieuses en ville ?\nQuels comportements augmentent le risque de problèmes de santé en ville ?", "url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Visual+Field+Tests&page=4#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment évaluer l'impact de la pollution urbaine sur la santé ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'impact se mesure par des études épidémiologiques et des indicateurs de santé." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour diagnostiquer les maladies liées aux villes ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de laboratoire, des examens cliniques et des enquêtes de santé sont utilisés." } }, { "@type": "Question", "name": "Comment identifier les zones à risque sanitaire en ville ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "L'analyse géospatiale et les données de santé publique aident à identifier ces zones." } }, { "@type": "Question", "name": "Quels indicateurs de santé sont pertinents en milieu urbain ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les taux de maladies respiratoires, cardiovasculaires et d'obésité sont des indicateurs clés." } }, { "@type": "Question", "name": "Comment évaluer l'accès aux soins en ville ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'accès se mesure par la distance aux établissements de santé et la disponibilité des services." } }, { "@type": "Question", "name": "Quels symptômes sont liés à la pollution de l'air ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent toux, essoufflement, irritation des yeux et fatigue." } }, { "@type": "Question", "name": "Comment la vie urbaine affecte-t-elle la santé mentale ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Le stress, l'anxiété et la dépression sont souvent exacerbés par la vie urbaine." } }, { "@type": "Question", "name": "Quels symptômes sont associés à la chaleur urbaine ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent déshydratation, épuisement et coups de chaleur." } }, { "@type": "Question", "name": "Quels signes indiquent une mauvaise qualité de l'eau en ville ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des signes incluent des maladies gastro-intestinales et des éruptions cutanées." } }, { "@type": "Question", "name": "Quels symptômes sont liés à l'isolement social en ville ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "L'isolement peut entraîner des symptômes de dépression et d'anxiété." } }, { "@type": "Question", "name": "Comment prévenir les maladies liées à la pollution en ville ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Des politiques de réduction de la pollution et des campagnes de sensibilisation sont essentielles." } }, { "@type": "Question", "name": "Quelles mesures peuvent réduire le stress urbain ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Promouvoir des espaces verts et des activités communautaires aide à réduire le stress." } }, { "@type": "Question", "name": "Comment améliorer la qualité de l'eau en milieu urbain ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des systèmes de filtration et des contrôles réguliers de la qualité de l'eau sont nécessaires." } }, { "@type": "Question", "name": "Quelles stratégies aident à prévenir les coups de chaleur ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Éduquer sur l'hydratation et l'ombre, et créer des refuges frais sont des stratégies clés." } }, { "@type": "Question", "name": "Comment favoriser la santé mentale en milieu urbain ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Encourager le soutien social et l'accès à des services de santé mentale est crucial." } }, { "@type": "Question", "name": "Quels traitements sont efficaces contre les maladies respiratoires urbaines ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les bronchodilatateurs, corticostéroïdes et thérapies respiratoires sont courants." } }, { "@type": "Question", "name": "Comment traiter les effets de la chaleur extrême en ville ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement inclut l'hydratation, le repos et, si nécessaire, des soins médicaux." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour le stress urbain ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie cognitivo-comportementale et les médicaments peuvent aider à gérer le stress." } }, { "@type": "Question", "name": "Comment traiter les maladies liées à l'eau contaminée ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement inclut l'hydratation, des antibiotiques et des soins symptomatiques." } }, { "@type": "Question", "name": "Quels traitements sont recommandés pour l'anxiété urbaine ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les thérapies psychologiques et les médicaments anxiolytiques sont souvent prescrits." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir à cause de la pollution ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des maladies respiratoires chroniques et des cancers." } }, { "@type": "Question", "name": "Quels risques de santé sont liés à l'isolement social ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "L'isolement peut entraîner des maladies cardiovasculaires et des troubles mentaux." } }, { "@type": "Question", "name": "Quelles complications peuvent résulter de la chaleur extrême ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des coups de chaleur, des déshydratations sévères et des décès." } }, { "@type": "Question", "name": "Comment la qualité de l'eau affecte-t-elle la santé ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Une mauvaise qualité de l'eau peut entraîner des infections et des maladies gastro-intestinales." } }, { "@type": "Question", "name": "Quelles complications sont liées à la vie urbaine ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent l'anxiété, la dépression et des maladies chroniques." } }, { "@type": "Question", "name": "Quels facteurs de risque sont associés à la pollution urbaine ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'industrialisation, le trafic routier et l'urbanisation rapide." } }, { "@type": "Question", "name": "Comment le stress urbain influence-t-il la santé ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Le stress peut aggraver des conditions comme l'hypertension et l'anxiété." } }, { "@type": "Question", "name": "Quels sont les risques liés à la chaleur en milieu urbain ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes âgées et celles avec des maladies chroniques sont particulièrement à risque." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de maladies infectieuses en ville ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "La densité de population et l'accès limité à l'eau potable augmentent les risques." } }, { "@type": "Question", "name": "Quels comportements augmentent le risque de problèmes de santé en ville ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Le tabagisme, la sédentarité et une alimentation déséquilibrée sont des comportements à risque." } } ] } ] }

Sources (10000 au total)

Smoking Cessation May Reduce Risk of Visual Field Progression in Heavy Smokers.

The earlier a person quits smoking the more likely is the optic nerve be spared from damage.... To investigate the effect of smoking cessation on visual field (VF) progression in glaucoma.... Primary open angle glaucoma patients with a minimum of 3 years follow-up and 5 VFs were included. Linear mixed models were used to investigate the effects of smoking on the rates of 24-2 VF mean devia... Five hundred eleven eyes of 354 patients were included over the mean follow-up of 12.4 years. Mean baseline age (95% confidence interval) was 62.3 (61.2, 63.4) years. One hundred forty nine (42.1%) pa... After ≥25 years of smoking cessation, the risk of VF progression in former heavy smokers becomes similar to never smokers. Long-term smoking cessation may be associated with lower VF progression in gl...

Correlation between Interocular Asymmetry of Corneal Hysteresis and Visual Field Defect in Glaucoma.

To evaluate the relationship between interocular asymmetries of corneal hysteresis (CH) and visual field defects in Korean patients with glaucoma.... A total of 444 eyes from 222 participants with glaucoma in at least one eye were enrolled. CH was measured using an ocular response analyzer (Reichert Technologies Inc). Eyes of each participant were ... Median (interquartile range) MD value was -3.71 dB (-6.87 to -1.30 dB) in the better eye and -10.20 dB (-16.32 to -5.62 dB) in the worse eye. When the correlation between the asymmetry of the MD value... The interocular asymmetry of CH was significantly correlated with the interocular asymmetry of visual field defects in glaucoma....

Comparing the Accuracy of Peripapillary OCT Scans and Visual Fields to Detect Glaucoma Worsening.

To compare the accuracy of detecting moderate and rapid rates of glaucoma worsening over a 2-year period with different numbers of OCT scans and visual field (VF) tests in a large sample of glaucoma a... Descriptive and simulation study.... The OCT sample comprised 12 150 eyes from 7392 adults with glaucoma or glaucoma suspect status followed up at the Wilmer Eye Institute from 2013 through 2021. The VF sample comprised 20 583 eyes from ... Within-eye rates of change in retinal nerve fiber layer (RNFL) thickness and mean deviation (MD) were measured using linear regression. For each measured rate, simulated measurements of RNFL thickness... The accuracy of diagnosing moderate and rapid rates of glaucoma worsening for different numbers of OCT scans and VF tests over a 2-year period.... Accuracy was less than 50% for both OCT and VF when diagnosing worsening after a 2-year period. OCT accuracy was 5 to 10 percentage points higher than VF accuracy at detecting moderate worsening and 1... More frequent OCT scans and VF tests are needed to improve the accuracy of diagnosing glaucoma worsening. Accuracy greatly increases when relying on both OCT and VF to detect worsening.... The author(s) have no proprietary or commercial interest in any materials discussed in this article....

Two-Year Visual Field Outcomes of the Treatment of Advanced Glaucoma Study (TAGS).

to compare visual field (VF) progression between the 2 arms of the Treatment of Advanced Glaucoma Study (TAGS).... Post hoc analysis of VF data from a 2-arm, multicenter, randomized controlled clinical trial.... A total of 453 patients with newly diagnosed advanced open-angle glaucoma in at least 1 eye from 27 centers in the United Kingdom were randomized to either trabeculectomy (n = 227) or medication in th... This study analyzed 211 eyes in the trabeculectomy first arm and 203 eyes in the medication first arm. The average RoP (estimate [95% credible intervals]) was -0.59 [-0.88, -0.31] dB/year in the medic... There was no significant difference in the average RoP at 2 years....

Visual Field Endpoints for Neuroprotective Trials: A Case for AI-Driven Patient Enrichment.

To evaluate whether an artificial intelligence (AI) model can better select candidates that would demonstrate visual field (VF) progression, in order to shorten the duration or the number of patients ... Retrospective cohort study.... 7428 eyes of 3871 patients from the University of Washington Department of Ophthalmology VF Dataset were included. Progression was defined as at least 5 locations with >7 dB of change compared with ba... A total of 13% of all patients met the criteria for progression at 5 years. Differences in survival were observed when stratified by MD and age (P < .0001). Those at risk of progression included patie... An AI model can identify high-risk patients to substantially reduce the number of patients needed or study duration required to meet clinical trial endpoints....

Fast Progressors in Glaucoma: Prevalence Based on Global and Central Visual Field Loss.

To determine the prevalence of fast global and central visual field (VF) progression in individuals with glaucoma under routine care.... Observational study.... Six hundred ninety-three eyes of 461 individuals with glaucoma followed up over a median of 4.5 years.... This study included (1) patients at a private ophthalmology clinic in Melbourne, Australia, and (2) individuals in 2 prospective longitudinal observational studies across 3 sites in the United States.... Prevalence of progression based on the rate of MD and the MTD... Based on the MD and the MTD... This study found that approximately 1 in 8 eyes with glaucoma receiving routine care showed fast progression based on global MD values (< -1.0 dB/year) and that nearly 1 in 3 eyes showed a < -0.5 dB/y... Proprietary or commercial disclosure may be found after the references....

Accuracy of Visual Fields in Localizing MRI Lesions in Posterior Cerebral Artery Infarction.

The representation of the visual field in visual cortex was established over a century ago by correlating perimetric defects with the estimated location of war wounds. The availability of high-definit... Homonymous hemianopias disclosed on automated visual fields (HVFs) were drawn from an electronic medical record search from 2009 to 2020 at the Michigan Medicine, a tertiary care academic medical cent... Among the 77 VFDs confined to 1 hemifield, 74 (96%) correctly predicted the side of the visual cortex lesion. In 3 cases, the MRI lesion in the opposite cerebral hemisphere was not foretold. Among the... In this study of PCA ischemic stroke, VFDs limited to 1 hemifield were accurate in locating the side and quadrant of the MRI visual cortex lesions. However, the quadrantic VFDs sometimes failed to pre...

Baseline 10-2 Visual Field Loss as a Predictor for Future Glaucoma Progression.

Presence of baseline 10-2 visual field (VF) loss was the strongest predictor of future rate of 24-2 VF loss and development of new 24-2 progression events, suggesting a role for 10-2 VF testing in bas... The purpose of this study is to examine the relationship between baseline 10-2 VF loss and future 24-2 VF loss.... Subjects were participating in a prospective longitudinal study within a VA Medical Center outpatient eye clinic. Eligibility required 2 good quality baseline 10-2 VF tests followed by a minimum of 5 ... We studied 394 eyes of 202 subjects (119 primary open angle glaucoma and 83 glaucoma suspect). Over 6.7 (±1.5) years, 9.9 (±2.3) good quality 24-2 VF tests were completed. In mixed model regression an... Baseline 10-2 VF defect was the most effective predictor of subsequent 24-2 VF progression in this study. These findings imply that presence of baseline 10-2 VF loss may provide unique value for predi...